SCHEMBL365141

SCHEMBL365141

CS(=O)(=O)NC(=O)c1ccc(OCc2ccccc2F)cc1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAOB P27338 4/20 0.65
PARP15 Q460N3 1/20 0.61
PARP14 Q460N5 1/20 0.61
PARP10 Q53GL7 1/20 0.61
SCN3A Q9NY46 2/20 0.52
ALDH1A1 P00352 1/20 0.51
LMNA P02545 1/20 0.51
SCN9A Q15858 2/20 0.50
SCN5A Q14524 1/20 0.50
LPAR1 Q92633 1/20 0.50
LPAR5 Q9H1C0 1/20 0.50
SENP7 Q9BQF6 3/20 0.49
NPC1 O15118 2/20 0.49
CASP3 P42574 2/20 0.49
RAB9A P51151 2/20 0.49
SENP8 Q96LD8 2/20 0.49
SENP6 Q9GZR1 2/20 0.49
SMN1; SMN2 Q16637 1/20 0.49
TAAR1 Q96RJ0 1/20 0.49
MMP1 P03956 3/20 0.48

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL365343 0.90 MAOB (0.52) MAOBPARP15PARP14PARP10SCN3A
SCHEMBL14890039 0.85 MAOB (0.67) MAOBSCN9ASCN5AMMP1ADAM17
SCHEMBL14890368 0.85 SCN9A (0.54) MAOBSCN3AALDH1A1SCN9ASCN5A
SCHEMBL364245 0.85 MAOA (0.65) MAOBSCN3ASCN9ASCN5ANPC1
SCHEMBL365767 0.84 MAOB (0.67) MAOBSCN3ASCN9AMMP1ADAM17
SCHEMBL14889855 0.84 SCN9A (0.53) MAOBSCN3AALDH1A1SCN9ASCN5A
SCHEMBL365920 0.84 RORC (0.62) PARP14PARP10SCN3AALDH1A1SCN9A
SCHEMBL14890410 0.83 SCN9A (0.57) MAOBSCN3ASCN9ASCN5AMMP1
SCHEMBL364125 0.82 FFAR1 (0.54) SCN3ASCN9AADAM17PTPN1
SCHEMBL365173 0.81 MAOB (0.61) MAOBPARP10SCN3AALDH1A1SENP7

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9096500-B2 Acyl sulfonamide compounds PFIZER LIMITED (GB) 2015-08-04 US disclosed
EP-2593428-B1 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS PFIZER LTD (GB) 2014-11-19 EP disclosed
EP-2593428-A2 N-SULFONYLBENZAMIDES AS INHIBITORS OF VOLTAGE-GATED SODIUM CHANNELS Pfizer Limited (GB) 2013-05-22 EP disclosed
US-20130109701-A1 Chemical Compounds PFIZER LIMITED (GB) 2013-05-02 US disclosed
WO-2012007868-A2 CHEMICAL COMPOUNDS PFIZER LIMITED (GB) 2012-01-19 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130109701-A1 Chemical Compounds SCN1A, SCN1B, SCN7A MAOB 3660/4885PARP15 1143/4885PARP14 2045/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.